10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Heregulin β-1

Catalog # PVGS1461

Product Information

Primary Accession	Q02297-6
Species	Human
Sequence	Thr176-Lys246
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	
Biological Activity	ED_{50} ≤ 0.5 ng/ml, determined by the dose-dependent stimulation of the proliferation of human MCF-7 cells.
Expression System	CHO
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH_2O or PBS up to 100 μg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Neuregulins or neuroregulins are a family of four structurally related proteins (NRG1, NRG2, NRG3 and NRG4) that are members of the EGF family of proteins. Studies indicate neuregulins function in nervous system development with essential roles in vertebrate embryogenesis including: cardiac development, Schwann cell and oligodendrocyte differentiation, certain aspects of neuronal development, and the formation of neuromuscular synapses. Neuregulin 1 is essential for the normal development of the nervous system and the heart. It is produced in numerous isoforms by alternative splicing, allowing it to perform a variety of functions. All NRG1 isoforms contain an EGF-like domain that is required for direct binding to ErbB3 or ErbB4 receptor tyrosine kinases. The transmembrane NRG1 isoforms contain an extracellular domain that can be proteolytically cleaved to release soluble growth factors.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.